Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, announced today that it has shipped its 100th
Cytek Aurora CS system. This milestone is a clear indication of the
company’s continuing momentum – and of the scientific community’s
desire for Full Spectrum Profiling™ (FSP™) technology that
streamlines workflows, accelerates discoveries and maximizes
efficiency.
Launched in June 2021, the Cytek Aurora CS is
built on the same FSP™ technology comprising Cytek’s Aurora cell
analysis system. It delivers high-sensitivity capabilities at the
single-cell level to resolve and sort even the most challenging
cell populations – regardless of assay complexity or inherent
autofluorescence. With the Aurora CS, researchers can easily
transfer assays from analyzer to sorter without redesigning panels
or reconfiguring detector systems, allowing for resolution and
isolation of the same cell populations. Live cells or other
particles can be deposited in microtiter plates or tubes for
downstream studies, such as single-cell RNA sequencing, proteomics
and cell biology. Assays that have been designed and optimized on a
conventional flow cytometer can also easily be run on the Cytek
Aurora CS.
“This milestone is a testament to the fact that
our FSP technology – namely, flexibility, autofluorescence
extraction, reagent combinations, and one configuration for all
applications – is highly sought after,” said Todd Garland, chief
commercial officer for Cytek Biosciences. “From the Cytek® Cloud to
cFluor® reagent kits to our exceptional technical applications
support teams and much more, Cytek is firing on all fronts. The
market is embracing our ecosystem of complete solutions, and we
will continue to build on our successes that advance the next
generation of cell analysis.”
Cytek’s mission to provide a complete cell
analysis solution to customers has continued to accelerate in
recent months. By acquiring the Luminex flow cytometry and imaging
business earlier this year, Cytek expanded its core instrument
offerings and broadened the market and research areas it services.
Additionally, the introduction of new cFluor pre-optimized assays
and expanded reagent portfolios further enables scientists to
advance their research with downstream applications, gain deeper
insights, and fast-track discovery.
The company’s achievements are reflected in the
over 1,150 peer-reviewed publications referencing use of Cytek
solutions in research ranging from immuno-oncology to infectious
diseases and immunology. Citations for these publications can be
accessed at https://cytekbio.com/blogs/publications.
For more information on the Aurora CS, please
visit https://cytekbio.com/pages/aurora-cs or www.cytekbio.com.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Aurora and Northern Lights™ systems; its cell sorter, the
Aurora CS; the flow cytometer and imaging products under the Amnis®
and Guava® brands; and reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and
distribution channels across the globe. More information about the
company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system
and certain reagents for use therewith, which are available for
clinical use in countries where the regulatory approval has been
obtained from the local regulatory authorities, including China and
the European Union, Cytek’s products are for research use only and
not for use in diagnostic procedures. Please contact your local
sales representatives for the status of local regulatory
approval.
Cytek, Full Spectrum Profiling, FSP, Northern
Lights, cFluor, Amnis and Guava are trademarks of Cytek
Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and corporate Twitter account as channels of distribution
of information about its company, products, planned financial and
other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Cytek may use these channels to comply
with its disclosure obligations under Regulation FD. Therefore,
investors should monitor Cytek’s website, LinkedIn page, and
Twitter account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek Biosciences’ mission, product plans and
strategies. These statements are based on management’s current
expectations, forecasts, beliefs, assumptions and information
currently available to management. These statements also deal with
future events and involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as those relating to global economic and
market conditions; Cytek’s ability to integrate the operations and
employees of the acquired flow cytometry and imaging business from
Luminex and recognize the anticipated benefits of the transaction;
Cytek Biosciences’ dependence on certain sole and single source
suppliers; competition; market acceptance of Cytek Biosciences’
current and potential products; Cytek Biosciences’ ability to
manage the growth and complexity of its organization, maintain
relationships with customers and suppliers and retain key
employees; Cytek Biosciences’ ability to maintain, protect and
enhance its intellectual property; and Cytek Biosciences’ ability
to continue to stay in compliance with its material contractual
obligations, applicable laws and regulations. You should refer to
the section entitled “Risk Factors” set forth in Cytek Biosciences’
Quarterly Report on Form 10-Q filed with the SEC on May 9, 2023 and
other filings Cytek Biosciences makes with the SEC from time to
time for a discussion of important factors that may cause actual
results to differ materially from those expressed or implied by
Cytek Biosciences’ forward-looking statements. Although Cytek
Biosciences believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot provide any
assurance that these expectations will prove to be correct nor can
it guarantee that the future results, levels of activity,
performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to Cytek Biosciences as of the date hereof,
and Cytek Biosciences disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek Biosciences’ views as of any date subsequent to
the date of this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef5fb58d-bf97-4e1d-adf0-da7ea038ba20
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024